Eric Michael David | Chief Executive Officer
BridgeBio-Gene Therapy

Eric Michael David, Chief Executive Officer, BridgeBio-Gene Therapy

Eric Michael David is CEO of gene therapy at BridgeBio. He was a co-founder of Organovo, where he most recently served as Chief Strategy Officer and Executive Vice President of Preclinical Development. Prior to Organovo, Dr. David was an Associate Partner at McKinsey & Co, where he served stakeholders across the healthcare spectrum including biopharmaceutical companies, private equity firms, large public and private healthcare systems, academic medical centers, and foundations on topics ranging from operations to M&A and R&D strategy.  He was also Assistant Professor at The Rogosin Institute, adjunct faculty at The Rockefeller University, and a lecturer in Medicine at Weil Cornell Medical College. Dr. David received his clinical training in internal medicine at New York Presbyterian Hospital / Weill Cornell, his  MD from Columbia University College of Physicians and Surgeons, his JD from Columbia Law School and his BA in physics and fine arts from Amherst College. He is licensed to practice medicine in California and New York, and admitted to the Bar in New York.


Day 2: Thursday 20th May 2021 - Gene Therapy @ 14:00

Panel discussion: Immunogenicity for gene therapy

Key unresolved clinical issues in gene therapy: immunosuppression, re-dosing, and in-utero dosing

Day 2: Thursday 20th May 2021 - Gene Therapy @ 15:00

Workshop: Novel gene delivery systems: what’s available? Exosomes, transposons etc. considerations, challenges

last published: 10/May/21 08:45 GMT

back to speakers